1. Home
  2. RGNX
  3. RGNX News

Latest REGENXBIO Inc. (RGNX) News on April 2, 2025

Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old
RGNX

Clinical Trials Arena

13 days ago

Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old

RGNX

MT Newswires

14 days ago

Regenxbio Says New Data Support Potential Gene Therapy for Duchenne Muscular Dystrophy

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY
RGNX

PR Newswire

14 days ago

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner
RGNX

Simply Wall St.

16 days ago

REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner

RGNX

Thomson Reuters StreetEvents

19 days ago

Q4 2024 Regenxbio Inc Earnings Call

Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience
RGNX

GuruFocus.com

19 days ago

Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
RGNX

Zacks

19 days ago

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates

RGNX

Associated Press Finance

19 days ago

Regenxbio: Q4 Earnings Snapshot

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
RGNX

PR Newswire

19 days ago

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
RGNX

PR Newswire

23 days ago

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Will Regenxbio (RGNX) Report Negative Earnings Next Week? What You Should Know
RGNX

Zacks

a month ago

Will Regenxbio (RGNX) Report Negative Earnings Next Week? What You Should Know

Jim Cramer on REGENXBIO Inc. (RGNX): ‘This Thing Just Does Nothing But Go Down’
RGNX

Insider Monkey

a month ago

Jim Cramer on REGENXBIO Inc. (RGNX): ‘This Thing Just Does Nothing But Go Down’

RGNX

MT Newswires

a month ago

Regenxbio Closes Partnership With Nippon Shinyaku

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases
RGNX

PR Newswire

a month ago

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

a month ago

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Participate in Upcoming Investor Conferences
RGNX

PR Newswire

a month ago

REGENXBIO to Participate in Upcoming Investor Conferences

Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
RGNX

Zacks

a month ago

Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
RGNX

Benzinga

2 months ago

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

RGNX

MT Newswires

2 months ago

Regenxbio Shares Fall After Downgrade From Goldman Sachs

RGNX

MT Newswires

2 months ago

Goldman Sachs Downgrades REGENXBIO to Neutral From Buy, Cuts Price Target to $14 From $38

Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet
RGNX

Zacks

2 months ago

Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet

With 71% ownership of the shares, REGENXBIO Inc. (NASDAQ:RGNX) is heavily dominated by institutional owners
RGNX

Simply Wall St.

2 months ago

With 71% ownership of the shares, REGENXBIO Inc. (NASDAQ:RGNX) is heavily dominated by institutional owners

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025
RGNX

PR Newswire

2 months ago

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?
RGNX

Zacks

2 months ago

Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?

Gene therapies have been uneven for DMD — but these companies hope to turn the tide
RGNX

Pharma Voice

2 months ago

Gene therapies have been uneven for DMD — but these companies hope to turn the tide

Regenxbio and Nippon Shinyaku forge $810m gene therapy deal
RGNX

Pharmaceutical Technology

3 months ago

Regenxbio and Nippon Shinyaku forge $810m gene therapy deal

Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku
RGNX

BioPharma Dive

3 months ago

Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku

RGNX

MT Newswires

3 months ago

REGENXBIO, Nippon Shinyaku Partner to Advance Drug Candidates for Certain Genetic Disorders in US, Asia

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
RGNX

PR Newswire

3 months ago

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
RGNX

PR Newswire

3 months ago

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

Regenxbio price target lowered to $22 from $25 at BofA
RGNX

TipRanks

3 months ago

Regenxbio price target lowered to $22 from $25 at BofA

RGNX

MT Newswires

3 months ago

BofA Securities Adjusts Price Target on REGENXBIO to $22 From $25, Maintains Buy Rating

RGNX

MT Newswires

3 months ago

RBC Lowers Price Target on REGENXBIO to $30 From $35, Keeps Outperform, Speculative Risk

RGNX

Argus Research

3 months ago

RGNX: Lowering target price to $8.00

RGNX

Argus Research

3 months ago

RGNX: Rating increased to a HOLD

RGNX

Argus Research

4 months ago

RGNX: Raising target price to $8.00

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
RGNX

PR Newswire

4 months ago

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

RGNX

Argus Research

4 months ago

RGNX: Lowering target price to $7.00

RGNX

Argus Research

4 months ago

RGNX: Rating decreased to a SELL

Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy
RGNX

Pharmaceutical Technology

4 months ago

Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy

RGNX

MT Newswires

4 months ago

Update: Regenxbio Shares Rise After Positive Phase I/II Data on RGX-202 Gene Therapy for Duchenne Muscular Dystrophy

RGNX

MT Newswires

4 months ago

Sector Update: Health Care Stocks Mixed Premarket Monday

RGNX

MT Newswires

4 months ago

Regenxbio Reports Positive Phase I/II Data on RGX-202 Gene Therapy for Duchenne Muscular Dystrophy - Shares Up Pre-Bell

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
RGNX

PR Newswire

4 months ago

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy
RGNX

BioPharma Dive

4 months ago

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
RGNX

PR Newswire

5 months ago

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

RGNX

Argus Research

5 months ago

RGNX: Raising target price to $11.00

Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report
RGNX

Simply Wall St.

5 months ago

Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report

REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations
RGNX

Simply Wall St.

5 months ago

REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations

Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ...
RGNX

GuruFocus.com

5 months ago

Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ...

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
RGNX

Zacks

5 months ago

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates

RGNX

Associated Press Finance

5 months ago

Regenxbio: Q3 Earnings Snapshot

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
RGNX

PR Newswire

5 months ago

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

RGNX

Argus Research

5 months ago

RGNX: Lowering target price to $9.00

Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings
RGNX

GuruFocus.com

5 months ago

Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings

REGENXBIO to Participate in Upcoming Investor Conferences
RGNX

PR Newswire

5 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

5 months ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

The past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitable
RGNX

Simply Wall St.

5 months ago

The past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitable

RGNX

MT Newswires

5 months ago

Regenxbio Reports 97% Reduction in Injection Need for Wet AMD; Shares Rise Pre-Bell

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
RGNX

PR Newswire

5 months ago

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
RGNX

PR Newswire

5 months ago

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc
RGNX

GuruFocus.com

5 months ago

JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc

RGNX

Argus Research

6 months ago

RGNX: Rating increased to a HOLD

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference
RGNX

PR Newswire

6 months ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

RGNX

MT Newswires

7 months ago

Regenxbio Names Mitchell Chan CFO

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer
RGNX

PR Newswire

7 months ago

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

RegenxBio touts positive data for rare disease drug RGX-121
RGNX

Pharmaceutical Technology

7 months ago

RegenxBio touts positive data for rare disease drug RGX-121

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
RGNX

PR Newswire

7 months ago

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect

REGENXBIO to Participate in Upcoming Investor Conferences
RGNX

PR Newswire

7 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

RGNX

Argus Research

7 months ago

RGNX: What does Argus have to say about RGNX?

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
RGNX

PR Newswire

7 months ago

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

RGNX

Argus Research

7 months ago

RGNX: Lowering target price to $12.00

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
RGNX

PR Newswire

8 months ago

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet
RGNX

Zacks

8 months ago

Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet

REGENXBIO Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
RGNX

Simply Wall St.

8 months ago

REGENXBIO Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates
RGNX

Zacks

8 months ago

Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates

RGNX

Associated Press Finance

8 months ago

Regenxbio: Q2 Earnings Snapshot

REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

8 months ago

REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202
RGNX

PR Newswire

8 months ago

REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202

Insider Sale: CEO Curran Simpson Sells Shares of Regenxbio Inc (RGNX)
RGNX

GuruFocus.com

8 months ago

Insider Sale: CEO Curran Simpson Sells Shares of Regenxbio Inc (RGNX)

Goldman Sachs Predicts up to 165% Surge for These 2 ‘Strong Buy’ Stocks
RGNX

TipRanks

8 months ago

Goldman Sachs Predicts up to 165% Surge for These 2 ‘Strong Buy’ Stocks

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

8 months ago

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

RGNX

Argus Research

8 months ago

RGNX: What does Argus have to say about RGNX?

RGNX

Argus Research

9 months ago

RGNX: Raising target price to $14.00

Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
RGNX

Zacks

9 months ago

Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?

RGNX

Argus Research

9 months ago

RGNX: What does Argus have to say about RGNX?

Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
RGNX

Zacks

9 months ago

Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD

RGNX

Argus Research

9 months ago

RGNX: Lowering target price to $11.00

Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth?
RGNX

Insider Monkey

9 months ago

Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth?

Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
RGNX

Zacks

9 months ago

Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?

RGNX

MT Newswires

9 months ago

Regenxbio Enrolling New Group for Phase 1/2 Duchenne Muscular Dystrophy Trial

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
RGNX

PR Newswire

9 months ago

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
RGNX

Investor's Business Daily

9 months ago

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
RGNX

Zacks

9 months ago

FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label

RGNX

MT Newswires

9 months ago

Regenxbio Reports 'Successful' Meeting With FDA For RGX-121

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
RGNX

PR Newswire

9 months ago

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
RGNX

BioPharma Dive

9 months ago

Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short

Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
RGNX

Zacks

10 months ago

Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?

RGNX

MT Newswires

10 months ago

Regenxbio Names Curran Simpson President, CEO

Regenxbio CEO to step down after 15 years
RGNX

BioPharma Dive

10 months ago

Regenxbio CEO to step down after 15 years

Share on Social Networks: